Cisplatin, Fluorouracil, and Vinblastine Combination Therapy

The combination of cisplatin, fluorouracil (5-FU), and vinblastine is a chemotherapeutic regimen that has been studied primarily for treating advanced non-small cell lung cancer (NSCLC) and urothelial cancers. This combination utilizes three different cytotoxic agents with complementary mechanisms of action. ## Clinical Applications This combination has been investigated in several clinical trials, particularly for non-small cell lung cancer. In a Phase II study, patients with advanced or metastatic NSCLC were treated with 5-fluorouracil (initially 1.5 g/m² then reduced to 1.2 g/m²) and vinblastine (initially 4 mg/m² then reduced to 3 mg/m²) by 24-hour continuous infusion, along with cisplatin 30 mg/m² over 30 minutes[1]. The regimen showed a response rate of 44% among evaluable patients, with responses occurring primarily in lung and lymph nodes[1]. Another randomized Phase II trial compared 5-FU + cisplatin versus 5-FU + cisplatin + vinblastine in previously untreated non-resectable NSCLC. The triple combination showed a higher response rate (20% vs 11%) and slightly longer median survival (5.6 months vs 4.6 months) compared to the dual combination[2]. ## Dosing Regimens Several dosing schedules have been studied: - For NSCLC: 5-fluorouracil 1.2-1.5 g/m² and vinblastine 3-4 mg/m² by 24-hour continuous infusion, with cisplatin 30 mg/m² over 30 minutes[1] - Alternative regimens have used different dosing schedules depending on the cancer type and study protocol ## Toxicity Profile The main adverse effects observed with this combination include: - **Myelosuppression**: This was the predominant toxic effect, with significant leukopenia reported[1][2] - **Gastrointestinal effects**: Including nausea, vomiting, diarrhea, and mucositis[1] - **Neurotoxicity**: Peripheral neuropathy has been reported[1] - **Renal toxicity**: Associated primarily with the cisplatin component - **Fever**: Including episodes of granulocytopenic fever[2] In the comparative study, more frequent and severe leukopenia, fever, genitourinary toxicity, and pulmonary toxicity were reported with the triple combination compared to cisplatin plus 5-FU alone[2]. ## Efficacy and Limitations While this regimen showed response rates comparable to other active regimens in single-institution studies for NSCLC, it did not appear to enhance survival significantly[1]. One study concluded that schedule manipulation did not enhance the therapeutic index of these drugs in NSCLC[1]. For urothelial cancers, other combinations including cisplatin with different agents have shown more promising results, such as the CMV (cisplatin, methotrexate, and vinblastine) regimen, which demonstrated a 56% overall response rate in metastatic transitional cell carcinoma[6]. The combination has been largely superseded by newer regimens with improved efficacy or more favorable toxicity profiles in current clinical practice.